The FDA’s vaccine chief is ready to depart the company by the tip of April, a spokesperson with the Division of Well being and Human Providers confirmed to ABC Information.
Dr. Vinay Prasad, the director of the Heart for Biologics Analysis and Analysis (CBER), had made selections in current weeks that prompted concern within the pharmaceutical business. Final month his division had opted to not assessment an software for a brand new mRNA flu vaccine from pharmaceutical firm Moderna. Moderna later re-submitted the applying beneath totally different age parameters.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
